A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma by Chung, T.-H. et al.
A Novel Measure of Chromosome Instability Can Account
for Prognostic Difference in Multiple Myeloma
Tae-Hoon Chung1, George Mulligan2, Rafael Fonseca3, Wee Joo Chng1,4,5*
1Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore, 2Millenium: The Takeda Oncology, Cambridge, Massachusetts, United
States of America, 3Mayo Clinic Comprehensive Cancer Center, Scottsdale, Arizona, United States of America, 4Department of Medicine, Yong Loo Lin School of
Medicine, National University of Singapore, Singapore, Singapore, 5Department of Haematology-Oncology, National University Cancer Institute of Singapore, National
University Health System, Singapore, Singapore
Abstract
Multiple myeloma (MM) is characterized by complex genetic abnormalities whose complexity signifies varying degree of
chromosomal instability (CIN). In this study, we introduced a novel CIN measure, chromosome instability genome event
count (CINGEC), which considered both copy number aberrations and interstitial breakpoints from high-resolution genome-
wide assays. When assessed in two aCGH MM datasets, higher CINGEC was associated with poor survival. We then derived a
CINGEC-associated gene expression profile (GEP) signature, CINGECS, using a dataset that has both aCGH and GEP. Genes in
CINGECS were mainly involved in DNA damage responses besides in aneuploidy and other generic oncogenic processes
contrary to other CIN associated GEP signatures. Finally, we confirmed its survival association in three GEP datasets that
encompassed newly diagnosed patients treated with transplant-based protocol with or without novel agents for induction
as well as relapsed patients treated with bortezomib. Furthermore, CINGECS was independent of many GEP-based
prognostic signatures. In conclusion, our novel CIN measure has definite biological and clinical significance in myeloma.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy charac-
terized by the accumulation of monoclonal plasma cell population
in the bone marrow and pronounced chromosomal abnormalities.
[1,2] Almost all MM patients are characterized by genomic
abnormalities including chromosome number and structural
variations, although each case may differ significantly in the
complexity of these abnormalities. The observed complexity is a
clear indication of underlying genomic instability, the failure of
protective cellular mechanism against the development of genomic
abnormality and/or subsequent intrinsic oncogenic properties
such as proliferation. The overall process that increases the rate of
this genomic abnormality is conceptually captured as chromosome
instability (CIN). [3] Although it is well established that individual
abnormalities such as translocations (e.g. t(4;14) [4]) and deletions
(e.g. 17p deletion [5]) or ploidy status (e.g. hypodiploid [6]) are
associated with clinical outcomes, the true relevance of CIN in
myeloma is unknown.
The detection of chromosome number and structural variations
is used as a practical marker of CIN. In particular, recent
developments of array-based high-resolution, high-throughput
platforms such as array-based comparative genomic hybridization
(aCGH) and single nucleotide polymorphism (SNP) chips have
provided researchers with novel opportunities to investigate CIN
in cancer genomes with resolutions that have never been possible
with conventional assay techniques before [7–10].
In this study, we introduce a novel measure of CIN,
chromosome instability genome event count (CINGEC), which
incorporates structural alterations that are generally ignored in
previous CIN indices that emphasized chromosome number
variations and show that CINGEC is by itself a prognostic factor
in myeloma. Subsequently, we develop a CINGEC-associated
gene expression signature, CINGECS, from a public MM dataset
that has both aCGH and gene expression profile (GEP) and assess
biological mechanisms that are actively involved in the CIN
phenomena by consulting two pathway repositories, Kyoto
Encyclopedia of Genes and Genomes (KEGG) and gene ontology
(GO). We also apply CINGECS to three public GEP datasets to
examine its capacity to differentiate different prognostic groups
either alone or in the presence of other GEP-based signatures and
show that CINGECS is an independent prognostic factor in
myeloma.
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Materials and Methods
Chromosome Instability Genome Event Count (CINGEC)
CIN represents the tendency for a cell to be lenient towards
compromises against genome integrity. Since a cancer cell with a
more unstable genome will develop more aberration events, gain
or loss of genome segments, until it experiences a systemic crisis,
the degree of CIN of a genome can be assessed by counting the
number of aberration events it harbors. In this study, we introduce
CINGEC, the heuristic minimum number of aberration events
inferred from genomic profiles, as a novel measure of CIN.
For the estimation of aberration events, we introduce two
assumptions. First, we assume gains and losses are equally
probable in all genome regions regardless of their copy number
status. Second, we assume gains and losses of single or multiple
copy numbers can happen with equal probability for a genome
region. One consequence of these assumptions is that the chance
of observing aberration events that happen at different time points
sharing the same breakpoint is very slim. Another consequence is
that all aberrant segments, irrespective of their spans and copy
numbers, are equally important and should contribute as such to
the estimation of CINGEC index.
The CINGEC algorithm proceeds from a copy number
sequence of a chromosome s = (s [1], …, s[n]), (s[i] M {-p, …,
q}; p, q .0; s[i] ? s[i+1]) obtained after discretizing aCGH data
into copy number levels (CNLs) using segmentation (Figure 1).
Here, positive and negative values represent different levels of
gains and losses, respectively. Obviously, copy number sequence is
composed of aberrant subsequences delimited by normal copy
number segments (CNL=0). In CINGEC, the number of
aberration events of a chromosome is estimated by the sum of
aberration events from aberrant subsequences. The number of
aberration events of an aberrant subsequence increases by 1 if
CNL transits into a new one (s[i] 1 {s[j] (j,i)}) or CNL transits
into earlier than the immediate previous level (s[i] = s[m], m,i-1).
The latter criterion is based on the observation that the chance of
two or more boundaries of independent aberration events
coinciding with each other is very slim and it is more natural to
assume an intervention of another aberration event that forces
different breakpoints align with each other. If CNL returns to any
of its previous levels, all intermediate CNLs between the departing
and returning events will be expunged and estimation moves to
next CNL. Final CINGEC estimate is the sum of all aberration
events in autosomal chromosomes to avoid complications from sex
chromosomes. Algorithmic details with an illustrative example are
described in Method S1.
Gene Expression Signature (CINGECS) Construction
Agilent 244K chip aCGH data of 254 MM patients from
Multiple Myeloma Research Consortium (MMRC) reference
collection were downloaded from Gene Expression Omnibus
(GEO; GSE26849). [7] We segmented the aCGH data by using
the CBS algorithm [11] implemented in ‘DNACopy’ R library
[12] using default parameters and CINGEC values were
estimated. MAS5 preprocessed Affymetrix HG-U133 Plus 2.0
GEP data for 304 MM patients from MMRC reference collection
were downloaded from GEO (GSE26760). 246 of the MMRC
samples had both aCGH and GEP data. We split CINGEC values
of these samples into 4 quartiles and the differential gene
expression between top and bottom quartile CIN groups was
examined using the SAM algorithm [13] implemented in
‘siggenes’ R library [14]. Probesets with p-values #0.001 and
false discovery rate (fdr) #0.05 and at least 2-fold expression
difference between the top and bottom CIN groups were selected
as CINGECS, the CINGEC-associated GEP signature.
Figure 1. Schematic illustration of CINGEC algorithm for an artificial chromosome with a CNL sequence given by S= (0, -1, 0, 2, 0, -1,
-2, -1, 0, 1, 2, 0). Aberrant subsequences for S are S(A) = (-1), S(B) = (2), S(C) = (-1, -2, -1), S(D) = (1, 2) and the number of events (marked by triangles in
lower panels) for each subsequence following the algorithm is 1 for S(A), 1 for S(B), 2 for S(C), 3 for S(D) and the CINGEC for this chromosome is 7. Note
that the event count for S(B) is 1 as in S(A) because CNL simply transits 0R 2 in S(B). Also note that the event count for S(D) is 3 due to the last transition
2R 0 (a transition into a level earlier than the immediate previous level 1) at the end of segment. In the algorithm, we assumed that two rugged end
boundaries of levels 1 and 2 (as in S(C)) were truncated to an identical genomic locus by an additional event.
doi:10.1371/journal.pone.0066361.g001
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Pathway Analysis of CINGECS
In order to identify biological pathways enriched by member
genes of CINGECS, we utilized impact factor (IF) analysis [15]
implemented in Onto-Tools. [16] Contrary to many pathway-
based analysis algorithms that consider only the enrichment of
gene lists within specific pathways, IF analysis puts more emphasis
on pathways whose member genes show fold changes that are
congruent with underlying interaction topology. We also per-
formed the GO analysis to supplement limited information
obtained from IF’s KEGG-dependency.
Survival Analyses Using Public aCGH and GEP Data
Prognostic utility of CINGEC and CINGECS was assessed
through survival analysis using overall survival (OS). For CINGEC
survival analysis, we used CINGEC scores estimated on aCGH
datasets from the Mayo clinic (Mayo; Agilent 44K chip) [17] and
from the University of Arkansas Medical School (UAMS; Agilent
22K chip) [18] separately. For CINGECS survival analyses, we
used University of Arkansas dataset (UAMS; GSE2658; HG-U133
Plus 2.0) [19,20] of 559 newly diagnosed MM patients treated with
total therapy II & III, APEX clinical trial dataset (APEX;
GSE9782; HG-U133 A/B) of 188 relapsed patients treated with
bortezomib [21], and HOVON-65/GMMG-HD4 clinical trial
dataset (HOVON; GSE19784; HG-U133 Plus 2.0) of 290 newly
diagnosed MM patients [22,23]. For APEX dataset, we used only
HG-U133 A chip probesets in this study. Besides CINGECS, we
used prognostic GEP signatures known to be statistically
significant in MM and 2 previously reported CIN signatures that
were predictive of patient prognosis in diverse cancers for
comparison: 70-gene survival index developed by researchers
from the University of Arkansas Medical School (UAMS70) [20],
proliferation index (PI) [24], centrosome index (CNTI) [25,26],
15-gene survival index from Intergroupe Francophone du
Myelome study (IFM) [27], cell death genes affected by
homozygous deletion (HZDCD) [28], 7-gene survival index from
a detailed study of IL-6 dependent and independent MM cell lines
(HMCL7) [29], 92-gene survival index from HOVON-65/
GMMG-HD4 study (EMC92) [23], CIN index by Carter et al.
(CIN70) [30] and CIN index from sarcoma study (CINSARC)
[31]. (See Table S4 for full list of member probesets).
For each GEP dataset, we normalized the expression profile for
a probeset by dividing individual expression values with the
Figure 2. OS difference among different inter-quartile groups by (a) CINGEC, (b) GII of Mayo patient aCGH data and (c) CINGEC, (d)
GII of UAMS patient.
doi:10.1371/journal.pone.0066361.g002
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median across all samples. We, then, estimated the univariate
CINGECS index of a sample by CINGECS=U – D where U is
the logarithm (base 2) of median of normalized expression values
of up-regulated CINGECS members while D is the logarithm
(base 2) of median of normalized expression values over down-
regulated CINGECS member genes, respectively. For other
indices, the estimation was done as follows: indices UAMS70
and CNTI were estimated as indicated in their respective original
publications. All other indices were estimated using log2-
transformed median-normalized MAS5 signals as expression
levels. For signatures where probesets are split into up- or down-
regulation groups such as IFM and HZDCD, indices were
estimated as done in CINGECS. All other indices were estimated
as the median of expression levels of member probesets.
For each dataset, we performed univariate and multivariate
survival analyses using Cox proportional hazard model. First,
values from CINGEC index or GEP signature indices were
respectively split into 4 quartile groups and survival tests using
univariate Cox proportional hazard model were performed. For
multivariate Cox analysis, we first examined three CIN-associated
signatures (CINGECS, CIN70, CINSARC) to remove possible
confounding effects due to similarity in signature construction and
chose the best performing one (CINGECS) for further analysis.
Multivariate Cox analyses were subsequently performed with
remaining worsening GEP signatures from univariate analysis (HR
.1 and p,0.05) and CINGECS. Stepwise refinements were
applied at the end.
For data processing and analyses including survival analysis, we
used R system [32] and its standard library ‘survival’. [33].
Results
CINGEC and Survival
We first estimated CINGEC scores of two MM aCGH datasets,
60 patient samples of the Mayo clinic and 100 patient samples of
the UAMS collection, and compared them with the genome
instability index (GII) that measures the fraction of aberrant
genomic regions in a genome [34] (Figure S1). In both cases,
CINGEC and GII were significantly correlated; correlation 0.62
(Figure S1(c); p = 4.66861028) for Mayo patient sample data and
0.43 (Figure S1(d); p = 9.19461026) for UAMS patient aCGH
data. However, the data distribution suggests that aberration
events covering whole chromosomes or arms make big impact on
GII but little on CINGEC, whereas highly complicated copy
number profiles with numerous small scale interstitial abnormal-
ities clearly dominate samples with high CINGEC score (Figures
S1 (c) and (d)).
Since CIN is known to cause adverse effects on patient survival
in cancer, we tested if this was also the case in myeloma. Analysis
using aCGH data from Mayo clinic clearly indicated that patients
grouped according to their CINGEC score had significantly
different OS (Figure 2(a); HR=1.70 with 95% confidence interval
(CI) = 1.16–2.49 and p-value = 0.00671). In contrast, the survival
difference was not that significant when GII was used (Figure 2(b);
HR=1.60, CI = 1.09–2.33, p= 0.0158). In particular, the survival
difference between the top quartile of CINGEC score and the rest
quartiles combined (HR=4.38, CI = 1.72–11.16, p = 0.00197)
were substantially greater than in GII (HR=2.74, CI = 1.12–6.74,
p = 0.0281).
We next validated if this effect of CINGEC on prognosis was
reproducible in an independent MM aCGH dataset. In the
UAMS aCGH dataset where patients were treated on the total
therapy II protocol, patients grouped according to their CINGEC
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CI= 1.11–2.72, p = 0.0164) while GII-based patient groups were
not (Figure 2(d); HR=1.56, CI = 0.96–2.54, p = 0.0758).
CINGECS Genes and Pathways
To further understand the molecular difference between MM
patients with high and low degrees of CIN, we analyzed the
MMRC reference collection using data from 246 samples where
both aCGH and GEP data were available. 214 probesets (160
genes; Table S1) were differentially expressed between samples in
top 25% and bottom 25% CINGEC. 189 probesets (144 genes)
were up-regulated and 25 probesets (16 genes) were down-
regulated in the high CINGEC group.
As expected, many genes implicated in aneuploidy and DNA
damage response were over-expressed in high CIN samples. Key
regulators of cell cycle checkpoints, in particular those involved in
the G2/M checkpoint (CDK1, CCNA2, CCNB1, CCNB2) and
the mitotic checkpoints (AURKA, BUB1, BUB1B, CENPA,
MAD2L1, NDC80, NEK2, PTTG1, TTK), were clearly over-
expressed in high CIN samples. E2F, CDC gene families are well
known cell cycle genes, and BIRC5, CENPA/F/H/K/N, KIF
gene family, ZWINT are known to code proteins involved in
kinetochore and microtubule attachment. On top of this, genes
involved in mismatch repair pathway (EXO1, MSH2, PCNA,
POLE2, RFC3/4/5), homologous recombination pathway
(BRCA1, RAD51AP1), DNA damage signaling (CHEK1,
RRM2, CCNB1/2, CDK1), and Fanconi anemia pathway
(FANCI, UBE2T) were also over-expressed in high CIN samples.
Furthermore, many genes in cancer-related pathways were also
over-expressed in high CIN samples including proliferation
(ASPM, CKS1B, MCM gene family, TOP2A, TTK, TYMS)
and cancer testis antigens (MAGE family).
To make the observations from the list of CIN signature genes
more concrete, pathways that were implicated by differentially
expressed genes in high CIN MM were assessed by using the IF
analysis first and then further complemented with the GO analysis
(Table 1 and Figure S2). As expected, pathways implicated in
aneuploidy (cell cycle and DNA replication) and DNA damage
response (mismatch repair, nucleotide excision repair, p53
signaling pathway) were significantly enriched in the high CIN
group. The results of GO analysis further consolidated the IF
analysis results. The list of statistically significant biological process
GO terms (Table S2) contained numerous cell cycle related terms
(cell cycle (GO:0007049), cell division (GO:0051301), spindle
organization (GO:0007051), mitosis (GO:0007067) etc.), DNA
damage response terms (response to DNA damage stimulus
(GO:0006974), DNA repair (GO:0006281), nucleotide-excision
repair, DNA gap filling (GO:0006297) etc.), and oncogenic process
terms (DNA replication (GO:0006260), cell proliferation
(GO:0008283) etc.). CINGECS therefore appears to describe the
CIN phenotype quite comprehensively. These functional associ-
ations of member genes also explain overwhelming dominance of
up-regulated genes in high CIN samples in CINGECS.
CINGECS and Disease Prognosis
In order to assess the clinical relevance of CINGECS, we
examined the association between CINGECS and OS using
multiple public MM datasets. OS among CINGECS inter-quartile
risk groups was statistically different in UAMS dataset (Figure 3(a);
HR=1.55, CI = 1.26–1.99, p = 3.2661025), in APEX dataset
(Figure 3(b); HR=1.51, CI = 1.27–1.79, p = 2.161026), and in
HOVON dataset (Figure 3(c); HR=1.53, CI = 1.26–1.85,
p = 1.1861025), respectively. In terms of clinical characteristics,
there was no significant segregation of TC class across the
CINGECS risk groups except for significantly more 11q13 cases in
Figure 3. OS difference among different risk groups by CINGECS. (a) UAMS, (b) APEX, (c) HOVON dataset.
doi:10.1371/journal.pone.0066361.g003
Table 2. Multivariate comparison of CIN-associated GEP
signatures.
Dataset Signature HR (CI) P
UAMS CINGEC 1.51 (1.20–1.91) 0.000483
CIN70 0.92 (0.60–1.40) 0.697
CINSARC 1.15 (0.75–1.76) 0.530
APEX CINGEC 1.56 (1.28–1.89) 6.2961026
CIN70 1.04 (0.65–1.67) 0.869
CINSARC 0.82 (0.52–1.31) 0.409
Hovon CINGEC 1.31 (1.06–1.61) 0.0127
CIN70 0.77 (0.43–1.35) 0.361
CINSARC 1.87 (1.06–3.30) 0.0308
HR=Hazard Ratio; CI = 95% Confidence Interval; P = p-value.
doi:10.1371/journal.pone.0066361.t002
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the high-risk CINGECS group in UAMS dataset (Table S3).
Strikingly, CKS1B amplification was significantly more common
in the high risk CIN group in UAMS dataset (65.1% in the highest
CINGECS risk group compared to 28.1% in the lowest
CINGECS risk group).
The prognostic utility of CINGECS in the presence of other
GEP-based prognostic signatures was assessed by multivariate Cox
proportional hazard analysis. First, to minimize the confounding
effect, we compared CINGECS with two other CIN-associated
signatures, CIN70 and CINSARC, that share substantial propor-
tion of their member probes with CINGECS (33 and 42 probes
out of 70 and 67 total probes, respectively; Figure S3) in three
representative public datasets of MM (table 2). CINGECS
consistently performed the best among CIN signatures in all
datasets and retained for further multivariate analysis with various
other prognostic GEP signatures of MM.
In UAMS dataset, all signatures considered in this study were
statistically significant for OS in univariate analyses (Table 3;
individual survival curves in Figure S4) with CINGECS inferior
only to UAMS70 (HR=1.74, CI = 1.43–2.11, p= 3.3361028)
and EMC92 (HR=1.54, CI = 1.28–1.87, p= 7.461026). On
multivariate analysis, however, CINGECS (HR=1.33,
CI = 1.07–1.66, p = 0.0119) remained as an independent risk
factor besides UAMS70 (HR=1.54, CI = 1.25–1.90,
p = 5.9161025) and HMCL7 (HR=1.20, CI = 1.01–1.44,
p = 0.0428). For OS in APEX dataset, all signatures except PI
were statistically significant with CINGECS inferior only to
EMC92 (HR=1.53, CI = 1.30–1.82, p= 6.4061027) in univariate
analyses (Table 3; individual survival curves in Figure S5).
However, only CINGECS (HR=1.38, CI = 1.16–1.64,
p = 0.000258) and EMC92 (HR=1.43, CI = 1.20–1.71,
p = 5.8761025) were statistically significant on multivariate
analysis. For OS in HOVON dataset, all signatures except
HMCL7 were statistically significant in univariate analyses with
EMC92 (HR=2.27, CI = 1.85–2.80, p= 7.99610215), UAMS70
(HR=1.66, CI = 1.37–2.02, p = 2.2661027), and PI (HR=1.62,
CI = 1.34–1.97, p = 1.0261026) superior to CINGECS (Table 3;
individual survival curves in Figure S6). However on multivariate
analysis, only EMC92 (HR=2.14, CI = 1.73–2.65,
p = 3.29610212) remained statistically significant beside CIN-
GECS (HR=1.26, CI = 1.04–1.53, p = 0.0198). Therefore, CIN-
GECS was associated with poor outcome independent of other
Table 3. Summary of univariate and multivariate Cox proportional hazard analysis with stepwise refinement using various
prognostic GEP signatures for OS in UAMS, APEX, and HOVON datasets.
Univariate Multivariate
Data Signature HR (CI) P HR (CI) P
UAMS CINGECS 1.55 (1.26–1.99) 3.2661025 1.33 (1.07–1.66) 0.0119
PI 1.24 (1.04–1.49) 0.0189
CNTI 1.30 (1.08–1.56) 0.00483
UAMS70 1.74 (1.43–2.11) 3.3361028 1.54 (1.25–1.90) 5.9161025
IFM 1.42 (1.18–1.72) 0.000244
HMCL7 1.22 (1.02–1.45) 0.0319 1.20 (1.01–1.44) 0.0428
HZDCD 1.37 (1.14–1.65) 0.000781
EMC92 1.54 (1.28–1.87) 7.461026
Overall 3.1861029
APEX CINGECS 1.51 (1.27–1.79) 2.196026 1.38 (1.16–1.64) 0.000258
PI 0.97 (0.82–1.14) 0.686
CNTI 1.25 (1.07–1.47) 0.00537
UAMS70 1.42 (1.20–1.68) 6.2961025
IFM 1.28 (1.09–1.51) 0.00209
HMCL7 0.84 (0.71–0.98) 0.0268
HZDCD 1.30 (1.10–1.54) 0.00215
EMC92 1.53 (1.30–1.82) 6.4061027 1.43 (1.20–1.71) 5.8761025
Overall 2.7161029
Hovon CINGECS 1.53 (1.26–1.85) 1.1861025 1.26 (1.04–1.53) 0.0198
PI 1.62 (1.34–1.97) 1.0261026
CNTI 1.30 (1.08–1.56) 0.00467
UAMS70 1.66 (1.37–2.02) 2.2661027
IFM 1.53 (1.26–1.85) 1.2761025
HMCL7 1.20 (1.00–1.43) 0.0507
HZDCD 1.29 (1.07–1.55) 0.00660
EMC92 2.27 (1.85–2.80) 7.99610215 2.14 (1.73–2.65) 3.29610212
Overall 0
HR=Hazard Ratio; CI = 95% Confidence Interval; P = p-value; Overall = collective p-value of final multivariate analysis with step-wise refinement.
doi:10.1371/journal.pone.0066361.t003
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GEP signatures in both newly diagnosed and relapsed myeloma
treated by either transplant-based therapy or novel agents.
Discussion
Cancer genomes contain genomic alterations of variable
complexity and CIN has been coined to characterize these
compromised genomes. The existence of CIN in cancer genome
clearly demonstrates malfunction or incompleteness of mecha-
nisms responsible for maintaining genome integrity and detailed
elucidation of molecular phenotypes associated with it can be very
useful in understanding the etiology of cancer as well as clinical
decision making since CIN has been shown to be associated with
disease progression and chemotherapeutic responses.[35–38].
MM is characterized by highly complex genomic alterations.
While specific genetic abnormalities have been associated with
disease outcome [39,40], the prognostic and biological relevance
of underlying genome instability/complexity has not been well
characterized in MM yet. Although we and others [26,27] have
reported high-risk signatures associated with expression of genes
involved in mitotic checkpoints and postulated that dysregulation
of genes involved in maintaining chromosomal integrity may
indicate underlying CIN as an important mediator of poor
prognosis, these were at best indirect inference as none of these
studies have shown an association between expression of these
signatures with a measure of CIN. A measure of CIN, CINGEC,
estimated by a novel algorithm described in this study that assesses
the number of aberration events necessary to account for both
aneuploidy and structural alterations captured in high-throughput
copy number data is shown to have direct association with disease
progression and survival in MM. In addition, its associated GEP
signature CINGECS was also significantly associated with poor
prognosis in three independent MM datasets. Furthermore, it was
independent of other prognostic signatures. Our results therefore
strongly implicate CIN as a biologically and prognostically
important factor in MM.
Comparison of CINGECS with two existing CIN signatures is
quite illuminating. Carter et al. introduced a signature (CIN70)
called total functional aneuploidy which is the sum of all absolute t
statistic between expression levels of genes in a cytoband against
average expression over the whole genome. [30] Recently, Chibon
et al. derived a signature from sarcoma data (CINSARC) by
combining aCGH imbalance comparison, histologic grade com-
parison, and CIN70 signature contents. [31] Since both CIN70
and CINSARC signatures are in principle based on aneuploidy
and cell cycle, genes related to mitosis and proliferation are
enriched in the signatures. However, CINGECS contains many
DNA damage response related genes such as response to DNA
damage stimulus, DNA repair, nucleotide-excision repair, DNA
gap filling in addition to those enriched in aneuploidy centered
signatures. This is a distinctive advantage of CINGEC estimation
algorithm that considers all structural alterations equally regardless
of genomic regions they span. It is also consistent with recent
findings that defects in the response to DNA double-strand breaks
[41] or in the homologous recombination [42] were implicated in
mediating CIN and disease progression. Despite overlaps between
genes constituting these CIN signatures, CINGECS but not
CIN70 or CINSARC was consistently an independent prognostic
factor in different datasets of MM. This suggests that aneuploidy
only accounts for part of the prognostic impact of CIN in myeloma
and the CINGECS more comprehensively describes the clinical
relevance of CIN in MM.
CINGECS risk groups are not associated with biological
features that endow preferential prognostic benefits or risks to
TC classes such as 4p16 and MAF classes with bad prognosis [19]
or D1 class with good prognosis. This suggests that CIN is
independent of primary genetic events in myeloma and is probably
driven by secondary mechanisms. However, the proportion of
samples that have amplified CKS1B gene, another known risk
factor [43], shows dramatic increase with CIN severity. This
association suggests that CKS1B amplification is a late genetic
event and a possible surrogate marker for advanced CIN. [44].
Finally, the prognostic impact of CINGECS is independent of
other prognostic GEP signatures in MM. In fact, it remained
independent in all datasets tested. This suggests that CIN
potentially confers a unique aspect of poor outcome that is not
captured in current landscape of prognostic signatures. This also
suggests that different GEP signatures may exert different effect on
myeloma outcome. As a consequence, one of the most important
challenges in the future would be to understand the relationship
between these independent signatures and whether they can be
combined for better prognostic utility.
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